Treatment of Chronic Alopecia Areata With Tildrakizumab: An Open-Label Pilot Study

March 2020 in “ International Journal of Dermatology ”

Karolina Louisa Suzanna Kerkemeyer, Rodney Sinclair

tildrakizumab monoclonal antibody interleukin-23 alopecia areata systemic therapies upper respiratory tract infection acne IL-23 AA

Studysummary This correspondence about the treatment of chronic alopecia areata with tildrakizumab reports no clinical results; the authors present an open-label pilot study setup. Our plain-language summary of this paper — not a Tressless recommendation.

In an open-label pilot study, tildrakizumab, a monoclonal antibody targeting interleukin (IL)-23, was tested for its efficacy in treating chronic alopecia areata (AA), a condition for which there are no reliably effective evidence-based treatments. Nine patients with moderate to severe AA, who were refractory to other systemic therapies, received three doses of tildrakizumab. At week 28, two patients showed a partial response, while the remaining seven showed no regrowth. Mild adverse effects included upper respiratory tract infection and acne. The study's limitations included a small sample size, lack of a control group, and inclusion of only patients who were refractory to multiple other therapies. The authors suggest that adequately powered, randomized, placebo-controlled, dose-ranging trials are needed to further examine the efficacy of tildrakizumab in AA.

View this study on minerva-access.unimelb.edu.au →

Discuss this study in the Community →

Research cited in this study

3 / 3 results

research Cyclosporine for Moderate-to-Severe Alopecia Areata: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of Efficacy and Safety

44 citations , April 2019 in “Journal of the American Academy of Dermatology”

This study observed that cyclosporine showed a trend toward improving alopecia areata symptoms compared to placebo, but the difference was not statistically significant.

research Treatment of Alopecia Areata: An Australian Expert Consensus Statement

95 citations , November 2018 in “Australasian journal of dermatology”

This consensus statement outlines a treatment algorithm for alopecia areata, discussing when to consider systemic treatment and how to assess outcomes, without providing new clinical results.

research Systemic Treatments for Alopecia Areata: A Systematic Review

41 citations , September 2018 in “Australasian journal of dermatology”

This review suggests that oral prednisolone pulse therapy and oral inosiplex may be effective for alopecia areata, but robust evidence from randomized controlled trials is lacking, highlighting the need for better-designed future studies.